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Abstract
Introduction The optimal management of patients with
symptomatic severe ostial vertebral artery stenosis (OVAS)
is currently unclear. We analyzed the long-term outcome of
consecutive patients with OVAS who received either
medical treatment (MT) or vertebral artery stenting (VAS).
Methods Thirty-nine (>70%) patients with severe OVAS
were followed for a mean period of 2.8 years. The decision
for VAS (n=10) or MT (n=29) was left to the clinician. The
Kaplan–Meier method was used to assess the risk of
recurrent stroke, transient ischemic attack (TIA), or death
over the study period.
Results Patients in the VAS group were significantly
younger and more likely to have bilateral VA disease
(P=0.04 and P=0.02). VAS was successfully performed in
all ten patients. The periprocedural risk within 30 days was
10% (one TIA). The overall restenosis rate was 10%. One
restenosis occurred after 9 months in a patient treated with
bare-metal stent. At 4 years of follow-up, VAS showed a
nonsignificant trend toward a lower risk for the combined
endpoint of TIA and stroke in posterior circulation
compared to medical treatment (10% vs. 45%, P=0.095;
relative risk (RR)=0.24, 95% confidence interval (CI)
0.031–1.85). Patients with bilateral VA disease had a
significantly lower recurrence risk after VAS compared
with medical treatment (0% vs. 91% at 4 years, P=0.004;
RR 0.10, 95% CI 0.022–0.49)
Conclusion VAS was performed without permanent compli-
cations in this small series of patients with symptomatic
severe OVAS. The long-term benefit seems to be confined to
patients with bilateral but not to those with unilateral VA
disease.
Keywords Ostial vertebral artery stenosis . Stenting .
Angioplasty . Secondary prevention . Long term
Posterior circulation strokes (PCS) account for approximately
25% of all ischemic strokes [1, 2]. In 20–25% of the PCS,
conventional or magnetic resonance angiography (MRA)
reveals a severe ostial stenosis or occlusion of the vertebral
artery (VA) [3, 4]. Occlusive disease involving the ostium of
the VA can cause a PCS by either hemodynamic compromise
or arterio-arterial embolism [5, 6].
Secondary prevention aims to improve the hemodynamic
situation and to eliminate the possible source of thrombo-
embolism. Preventive measures include medical treatment
(MT) and surgical or endovascular revascularization. MT
consists of antiplatelets, statins, and a thorough control of
the blood pressure in order to avoid hypotension. Because
of the difficult access to the VA origin, surgery is rarely
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performed in the clinical routine. Endovascular therapy is
less invasive and thus a promising alternative to surgery.
However, its long-term benefits compared with MT are
currently uncertain.
The only randomized trial comparing endovascular with
MT is the Carotid and Vertebral Artery Transluminal
Angioplasty Study (CAVATAS) [7]. The study failed to
show a benefit of endovascular treatment, but the number
of included patients was small (n=16). A larger randomized
trial, the Vertebral Artery Stenting Trial, has recently been
launched, though the results are not to be awaited soon [8].
The present study analyzed the long-term outcome of
consecutive patients with symptomatic ostial vertebral
artery stenosis (OVAS), who were admitted to a single
stroke center over a period of 10 years and received either
MT or vertebral artery stenting (VAS).
Methods
Patient selection
From January 2000 to July 2008, 39 consecutive patients
with a recently symptomatic (within 48 h) severe (>70%)
OVAS were admitted to a single university-based stroke
center. Demographic data, vascular risk factors, National
Institutes of Health Stroke Scale (NIHSS) score [9] on
admission, and stroke etiology according to the Trial of Org
10172 in Acute Stroke Treatment criteria [10] were assessed
prospectively by stroke neurologists. Data were entered into
a computer-based databank. The following stroke risk factors
were assessed: age, sex, hypertension (defined by preadmis-
sion history and medical records), diabetes mellitus (defined
by venous plasma glucose concentration of ≥7.0 mmol/l after
an overnight fast on at least two separate occasions
and/or ≥11.1 mmol/l 2 hours after the ingestion of 75 g of
oral glucose and on one other occasion during the 2-h test),
current cigarette smoking, hypercholesterolemia (plasma
cholesterol concentration >5 mmol/l), decreased plasma
high-density lipoprotein (level <1 mmol/l), increased
plasma low-density lipoprotein (level >3 mmol/l), increased
plasma triglycerides (level >1.6 mmol/l), coronary artery
disease, and peripheral artery disease.
The patients had suffered either an acute PCS (n=18) or
a transient ischemic attack (TIA; n=21) in the posterior
circulation. There were no alternative causes of stroke (e.g.,
cardiac sources of embolism, small artery disease, and other
determined stroke etiologies).
The diagnosis of PCS was based on the sudden onset of
focal neurological deficits from the vertebrobasilar territory
lasting for more than 24 h with corresponding findings on
brain imaging. Posterior circulation TIAs were assumed if
symptoms from the vertebrobasilar territory recovered
completely within 24 h. Brain imaging involved non-
enhanced computed tomography (CT) in 23 patients and
multimodal MRI (axial T1-, T2-, and intermediate-weighted
images, diffusion-weighted images, perfusion-weighted
images) in 30 patients (both imaging modalities were
performed in 14 patients). The diagnosis of proximal vertebral
artery stenosis was established by color-coded duplex
ultrasonography in all patients and verified by CT angiogra-
phy (CTA) in ten, contrast-enhanced MRA in 25, or digital
subtraction angiography (DSA) in 20 patients. The DSAwas
not preceded by CT or MR angiography in four patients.
A hemodynamically significant ostial stenosis was
suspected if color-coded duplex ultrasonography revealed
peak systolic velocities >100 cm/s at the origin of the
vertebral artery and an antegrade blood flow in the more
distal segments of the vessel [11]. CTA, MRA, and DSA
used the following formula to define the degree of stenosis:
(1−A/V)×100 (%), where Awas the diameter of the residual
lumen at the point of maximal stenosis and V the diameter
of the distal disease-free vertebral artery. This method is
similar to the one used to measure carotid artery stenosis in
the North American Symptomatic Carotid Endarterectomy
Trial [12]. The CTA or MRA axial source images were
used to define the diameter of the residual lumen. The
image analysis was performed by a neurologist (A.K.) and
an interventional neuroradiologist (G.S.) in consensus.
Treatment
The decision to treat patients medically (n=29) or by VAS
(n=10) was left to the discretion of the treating physician.
Reasons to perform VAS were: (1) intra-arterial thrombolysis
in two patients with a basilar artery thrombosis due to an ostial
occlusion or pseudo-occlusion of the dominant vertebral
artery in order to ensure the endovascular access to the basilar
artery [13]; (2) crescendo TIAs in patients under MT (n=3);
(3) hemodynamic TIA or PCS, in which symptoms had
occurred most likely because of arterial hypotension (n=5).
All patients undergoing VAS had no limiting comorbidities
and an estimated life expectancy greater than 5 years.
Medical treatment
MT included aspirin 100–00 mg/day (n=20), clopidogrel
75 mg/day (n=1), vitamin K antagonists (n=5), and the
combination of aspirin and clopidogrel (n=3). In addition,
20 patients were on statins (n=20), and 18 patients were
given antihypertensive drugs (n=18).
Vertebral artery stenting
Twelve VAS procedures were performed in ten patients to
treat 11 vertebral arteries with origin stenosis.
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All patients undergoing VAS received aspirin 100 mg
and clopidogrel 75 mg. Dual antiplatelet therapy was
continued for 12 months, and aspirin was continued
indefinitely.
Vascular access was gained through a femoral approach.
A 7- or an 8-F-long sheath or an arrow sheath was placed in
the proximal subclavian artery. An 8-F balloon catheter was
used if proximal protection of embolic events by reversed
flow was intended. The target ostial VA stenosis was passed
with microwire or a FilterWire if distal protection was used.
Using biplane roadmap, the balloon-expandable stent was
positioned across the stenosis over the 0.014-in. wire with
the proximal end of the stent placed in the subclavian
artery. At the origin of the vertebral artery, predilatation was
not performed. In one patient with a bilateral internal
carotid occlusion and a high-grade left vertebral artery
stenosis, right brachial access with a 5-F sheath was used
for the treatment of a symptomatic high-grade right
vertebral artery stenosis. The following drug-eluting (n=7)
and bare-metal (n=5) stents were used: Endeavor RX
(Medtronic Inc., Minneapolis, MN, USA) in six cases,
Taxus Express2 (Boston Scientific, Natick, MA, USA) in
one case, Herculink (Abbott Laboratories, Abbott Park, IL,
USA) in three cases, Titan-2-BAS (Hexacath, Rueil-
Malmaison, France) in one case, and Tetra-Megalink
(Guidant, Indianapolis, IN, USA) in one case. Two patients
received two stents each—in one patient, a restenting
procedure was needed because of restenosis after 9 months.
The restenosis was treated with a drug-eluting stent (DES)
in the bare-metal stent. In the other patient, both vertebral
arteries were treated.
Clinical endpoints
The primary efficacy endpoint was the freedom from TIA
and fatal and nonfatal PCS during the follow-up.
The primary safety endpoint was the solitary rate of
all-cause death, stroke-related death, any stroke including
hemorrhagic stroke and stroke in the anterior circulation,
myocardial infarction (MI), and any reintervention up to
30 days after the index event.
Secondary endpoints were the rates of any stroke (including
hemorrhagic and contralateral stroke), TIA, transient
retinal ischemia (amaurosis fugax), retinal infarction,
in-stent stenosis, repeated target vessel revascularization,
all-cause death, and stroke-related death during the
follow-up.
Procedural success
The procedural success was defined as: (1) achievement of
residual stenosis <30% and (2) absence of adverse events
during the hospital stay or within 24 h of the index procedure.
Methods of clinical and radiological follow-up
The medically treated patients were followed annually on a
scheduled basis. All patients underwent a clinical examination
and a color-coded duplex ultrasound. Clinical endpoint events
and medication were documented.
Patients who underwent VAS were followed at 30 days,
at 6 months, at 12 months after treatment, and annually
afterwards. All patients underwent a clinical examination
and a color-coded duplex ultrasound. Patients with ultrasound
findings suggesting in-stent stenosis underwent further
workup by CTA, MRA, and/or DSA. The MRA has been
demonstrated to overestimate the stenosis grade of the VA
origin in about 15% of the cases [14]. In our study, MRA and
CTA were used generally to confirm the findings of the
color-coded duplex ultrasonography. The latter has consid-
erably higher accuracy in proximal vertebral artery stenosis
quantification, with specificity up to 99% for stenoses
greater than 70% [15]. In-stent stenosis was defined as the
presence of <50% stenosis immediately after treatment, with
an increase of stenosis to >50% during follow-up.
If a patient developed new neurological symptoms
during the follow-up, she/he was managed according to
current guidelines for acute stroke treatment. The decision
to perform CT or MR brain imaging was guided by the
patients’ clinical condition and the time elapsed from the
symptom onset.
Statistical methods
Data are reported in frequency tables. Quantitative data are
expressed as mean values±1 SD. The NIHSS score for each
patient at admission is given as a median value. Differences
between groups and the effect of patient characteristics on
clinical and radiological endpoints were assessed using
Fisher’s exact test (for comparison of proportions), Student
t test (for comparison of continuous variables), and Mann–
Whitney U test (for comparison of ordinal variables). The
Kaplan–Meier method was used to determine the likelihood
of freedom from fatal and nonfatal PCS during follow-up.
The log-rank test was used to compare the cumulative
incidence curves between the treatment groups. Predictors of
recurrent events according to treatment assignment were
analyzed by a Cox proportional hazards model. Two-sided P
values less than 0.05 were considered statistically significant.
Results
Baseline clinical and radiologic characteristics
The baseline clinical and radiologic characteristics of all
patients (n=39) are given in Table 1. Twenty-nine patients
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received medical treatment only (medical group), and ten
patients underwent VAS (VAS group). Patients of the
medical group were older, had less severe neurological
deficits on admission, and were less often current smokers.
Both groups did not differ in terms of sex, type of the index
event (TIA or PCS), or vascular risk factors (except for current
cigarette smoking). There were significantly more patients
with occlusive disease of the contralateral vertebral artery in
the VAS group than in the medical group (P=0.02).
Primary safety endpoint (30-days follow-up)
VAS was performed within 0 to 2 days after the index
event. In the medical group, one patient died from basilar
artery thrombosis 22 days after the index event. In the VAS
group, a TIA occurred 1 day after the procedure. There
were no hemorrhagic strokes, strokes in the anterior
circulation, MI, or reinterventions within 30 days after the
index event.
Primary efficacy endpoint (long-term follow-up)
Outcome events during a mean follow-up of 2.8 years are
summarized in Table 2. Two fatal PCS, one nonfatal PCS,
and ten TIAs were observed in the medical group,
compared with one TIA in the stented group. In the medical
group, eight TIA and three strokes occurred in patients with
acetylsalicylic acid, one TIA with clopidogrel and one TIA
with oral anticoagulation.
At 4 years of follow-up, VAS showed a nonsignificant
trend toward a lower risk in the combined endpoint of TIA
and nonfatal and fatal PCS (10% vs. 45%, P=0.095; relative
risk (RR)=0.24, 95% confidence interval (CI) 0.031 – 1.85),
when compared to medical treatment (Fig. 1).
Table 2 Primary efficacy and secondary endpoints.
Events Probability of event at 4years HR (95% CI) P value
Stenting Medical Stenting Medical
Primary efficacy endpoints 1 13 10% 44.8% 0.24 (0.03–1.88) 0.14
TIA 1 10 10% 34.48% 0.32 (0.04–2.55) 0.26
Fatal PCS 0 1 0% 3.44% 0.0 (0.0–10E12) 0.56
Nonfatal PCS 0 2 0% 6.89% 0.0 (0.0–10E12) 0.42
Secondary endpoints 1 4 10% 13.79% 1.86 (0.18–18.76) 0.60
Hemorrhagic stroke 0 1 0% 3.44% 0.0 (0.0–10E12) 0.67
Any death 0 3 0% 10.34% 0.0 (0.0–10E12) 0.51
Anterior circulation stroke 0 1 0% 3.44% 0.0 (0.0–10E12) 1






Female, n (%) 12 (41) 2 (20) 0.22
Age, year (SD) 68 (8) 60 (13) 0.04
Follow-up, year (SD) 3.1 (2.7) 2.1 (1.5) 0.27
Index event, n (%)
TIA 22 (76) 5 (50) 0.12
PCS 7 (24) 5 (50) 0.12
NIHSS on admission, median (SEM) 1 (0.45) 3.5 (3.6) 0.03
Vascular risk factors, n (%)
Hypertension 17 (59) 7 (70) 0.52
Diabetes mellitus 7 (24) 2 (20) 0.79
Current smoker 3 (10) 6 (60) 0.001
Hypercholesterolemia 20 (69) 7 (70) 0.95
Coronary artery disease 5 (17) 0 0.16
Peripheral artery disease 1 (3) 0 0.55
Occlusive disease of the contralateral VA 11 (38) 8 (80) 0.02
Table 1 Baseline clinical and
radiologic characteristics.
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Cox regression analysis was used to assess for predictors of
recurrent PCS or TIA (Fig. 2). Sex, age >70 years, vascular
risk factors (except for hypertension), and stroke or TIA as
an index event did not influence the outcome, neither in the
medical nor in the stented group. Patients with occlusive
disease of the contralateral vertebral artery had a significantly
lower risk of recurrent PCS or TIA after VAS compared with
medical treatment (0% vs. 91% at 4 years, P=0.004; RR
0.10, 95% CI 0.022 – 0.49 Figs. 2 and 3). The risk of
recurrent PCS or TIA in patients with hypertension was
significantly higher after VAS than with medical treatment
(57% vs. 12% at 4 years, P=0.04; RR 27.8, 95% CI 1.13–
681; Fig. 2).
Secondary endpoints (long-term follow-up)
The secondary endpoint events are summarized in
Table 2. In the medical group, two patients died from
Fig. 1 Probability of TIA and fatal and nonfatal stroke stratified for
medical treatment (continuous line) and VAS (dashed line)
Fig. 2 Risk ratios according to
treatment assignment in
subgroups
Fig. 3 Probability of recurrent TIA or PCS stratified for medical
treatment (continuous line) and VAS (dashed line) in the subgroup of
patients with occlusive disease of the contralateral vertebral artery
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cancer 3 and 4 years after the index event, respectively.
One patient suffered a hemorrhagic stroke 2 months after
the index event, while taking oral anticoagulants; the
same patient died from pneumonia 2 years after the index
event. One patient suffered an ischemic stroke in the
anterior circulation 6 years after the index event. In the
stented group, an asymptomatic restenosis was diagnosed
9 months postprocedure. The patient was primary treated with
a bare-metal stent; then, he underwent reintervention
with a drug-eluting stent and remained asymptomatic
with no further restenosis during the following
12 months.
Discussion
Patients with symptomatic severe (>70%) OVAS face an
11% annual risk of recurrent PCS or TIA under medical
treatment. This risk is much lower (2.5%) after VAS,
though the difference is not statistically significant at the
4-year mark. Patients with occlusive disease of both vertebral
arteries have a significantly lower risk of stroke/TIA
recurrence after VAS compared with medical treatment. The
risk of recurrent events in patients with hypertension is
significantly higher in the endovascular than in the medical
group. These are the main results of the present small study.
a b c
ed
Fig. 4 Proximal protection device (Mono-MOMA). 57-year-old woman
with acute vertebrobasilar symptoms. a The angiography of the left
subclavian artery shows left-sided vertebral artery stenosis. b High-
resolution DSA confirms VA stenosis with thrombotic material in the
subclavian and vertebral artery. c Flow arrest with stagnating contrast
distal from the balloon in the proximal subclavian artery. Washout of the
contrast, distally from the origin of the vertebral artery, due to the
iatrogenic vertebral steal from right to the left. d Stenting procedure,
during proximal protection by inverted flow, in the left vertebral artery.
e Remodeling of the origin of the left vertebral artery
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To date, few studies have compared medical and
endovascular treatment in the secondary prevention of
patients with OVAS. The only randomized study, the
CAVATAS, failed to demonstrate the superiority of the
endovascular over the medical treatment [7]. However, this
study included only 16 patients with moderate to severe
(>50%) VA stenosis and did not consider occlusive disease
of the contralateral VA artery. During the follow-up of
4.7 years, no patient in either treatment group experienced a
vertebrobasilar territory stroke, but two patients experienced a
TIA at the time of endovascular treatment. Three patients in
each treatment arm died of myocardial infarction or carotid
territory stroke, and one endovascular patient had a nonfatal
carotid territory stroke. The study emphasized the importance
of the global reduction of vascular risk. The annual rates of
symptom recurrence were 11% and 5% in the endovascular
and the medical groups, correspondingly. These figures are
comparable with the annual risk of stroke/TIA recurrence
observed in the present study, though in our series there is a
nonsignificant trend in favor of the endovascular treatment.
There was a subgroup of patients—those with a bilateral
pathology of the VA—who derived a significant benefit from
VAS when compared to medical treatment (Figs. 2 and 3).
The hemodynamic compromise in patients with bilateral VA
stenosis seems to be a major contributor to the significantly
higher rate of recurrent vertebrovascular ischemia in the
medical group. Surprisingly, hypertensive patients had a
28-fold increased risk of stroke/TIA recurrence after VAS
than with medical treatment. However, the 95% confidence
interval ranged between 1.1 and 682, indicating that the
increased risk might be a chance observation due to the
skewed distribution of hypertensive patients in both
groups.
Several studies have assessed the technical success and
the safety of the endovascular treatment of patients with
OVAS [16–20]. Typically, the endovascular treatment was
associated with a high rate of technical success (up to
100%). Earlier studies performed percutaneous angioplasty
without stenting [7, 14]. Later on, bare-metal and drug-
eluting stents have been employed [15–18]. In the present
study, angioplasty with primary stenting was employed in
all patients. Five patients were treated with drug-eluting
stents, and five patients received bare-metal stents. The
procedure was successful in all ten patients (100%).
The major risk of endovascular treatment is dislodgement
and distal embolization of plaque and thrombotic debris,
which may lead to stroke. Previous studies have reported
6.4% periprocedural risk within 30 days postprocedure [21].
A recent study assessed the technical and clinical outcomes
of 72 patients with ostial vertebral stenoses [22]. In 23 (32%)
asymptomatic patients, VAS was performed as a primary
preventive measure. In the remaining patients, the OVAS
was symptomatic. Periprocedural stroke was associated with
attempted treatment of a tandem intracranial stenosis, while
traditional vascular risk factors were not. The risk of the
procedure likely depended on the severity of stenosis. In
contrast to this study, our series includes only patients with
symptomatic severe OVAS. In the VAS group, one TIA
occurred 1 day postprocedure (10%). There were no
hemorrhagic strokes, strokes in the anterior circulation, MI,
or reinterventions within 30 days after the index event. Our
results are consistent with other published series demonstrating
a low periprocedural risk of VAS.
There are currently only few studies using neuroprotection
devices (NPD) for vertebral artery stenting. The feasibility of
vertebral origin stenting using distal NPD was assessed in a
a b c
Fig. 5 Distal protection device (FilterWire). A 42-year-old man
suffering from recurrent symptoms of vertebrobasilar insufficiency.
a The angiography of the right subclavian artery demonstrates stenosis
of the right vertebral artery. b A distal protection device (FilterWire,
Boston Scientific) in place during PTA. c A remodeling of the origin
of the right vertebral artery after stent implantation (Taxus stent,
Boston Scientific)
Neuroradiology (2010) 52:371–379 377
series by Qureshi et al.[23] The authors reported no major
complications within the 30-day period. The use of proximal
NPD, however, seems to be confined only to cases with
high-risk lesions, where distal NPD can potentially lead to
device-related embolization during the passage of unstable
lesion (“unprotected” lesion crossing). A double-balloon
technique with simultaneous transfemoral and transbrachial
approach for angioplasty of high-risk subclavian and
vertebral origin stenoses has been proposed by Staikov et
al. in a previous report [24]. Nevertheless, since the benefit
of NPD in vertebral artery stenting is yet to be proven,
protection devices were applied in our series only by
exception. A distal protection and a proximal protection
with flow reversal were used in one patient each with high
risk of debris dislodgment (Figs. 4 and 5).
In VAS, restenosis is an important issue. In balloon
angioplasty without stenting, the restenosis rates reported in
the literature are very high (up to 100% at 1 year) [14].
Primary stenting reduces the restenosis rates to 10–45%
[25, 26], though the pathophysiology and the predicting
factors of restenosis are still under evaluation. Earlier
studies used bare-metal stents and reported high restenosis
rates (up to 67% at 6 months) [27]. More recently, drug-
eluting stents developed for coronary interventions have
been used to treat cerebrovascular lesions. The reported
restenosis rates were moderate to low, though the follow-up
intervals were relatively short (7% at 4 months [28], 0% at
11 months [29], <5% at 14 months [30]). In our series, one
asymptomatic restenosis occurred during the 4-year follow-
up. Notably, the only restenosis occurred in a patient treated
with a bare-metal stent. No further restenosis was observed
during a follow-up of 12 months, after treatment with a
DES of the in-stent stenosis in the bare-metal stent.
Our study has several limitations. First, treatment
assignment was not random, and comparisons between
medical and endovascular treatment should be interpreted
with caution. For example, medically treated patients were
significantly older, which may have contributed to the
higher rate of stroke/TIA recurrence. Furthermore, bilateral
VA stenosis was more frequent in the stented group.
Second, the small sample size precluded subgroup analyses.
For instance, it remains unclear whether clopidogrel is
superior to aspirin in the prevention of subsequent ischemic
stroke or TIA in the vertebrobasilar territory. Also, the role
of hypertension as a predictor of recurrent events seems to
be a chance observation due to the skewed distribution of
hypertensive patients in both groups.
In conclusion, VAS can be safely performed in patients
with symptomatic severe OVAS. The long-term benefit
however appears to be confined to patients with bilateral
but not to those with unilateral VA disease. Randomized
controlled trials are needed to define the optimum manage-
ment of patients with severe stenosis of the vertebral artery.
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